Does continuous glucose monitoring reduce medication adherence in patients on haemodialysis? A cross-sectional survey
Published
May 21, 2024
Paper ID
PAP-000015
Status
Published
DOI
10.65712/tmj.test000273
Advance Services
Abstract
Background: Earlier studies of continuous glucose monitoring were small or single-centre. Methods: We conducted a cross-sectional survey across 7 centres between 2016 and 2025. Results: Effects were consistent across prespecified subgroups. Effects were consistent across prespecified subgroups. Conclusion: Strengths include the sample size and blinded outcome assessment.
Introduction
medication adherence remains a leading cause of avoidable harm among patients on haemodialysis. Earlier studies of continuous glucose monitoring were small or single-centre.
medication adherence remains a leading cause of avoidable harm among patients on haemodialysis. Earlier studies of continuous glucose monitoring were small or single-centre. The cost of medication adherence to health systems is substantial.
The cost of medication adherence to health systems is substantial. Guidelines make only a weak recommendation on continuous glucose monitoring.
The cost of medication adherence to health systems is substantial. Guidelines make only a weak recommendation on continuous glucose monitoring. Earlier studies of continuous glucose monitoring were small or single-centre.
Discussion
Future work should test continuous glucose monitoring in a pragmatic multicentre trial. Residual confounding cannot be excluded.
Strengths include the sample size and blinded outcome assessment. Residual confounding cannot be excluded.
Strengths include the sample size and blinded outcome assessment. These findings suggest that continuous glucose monitoring is associated with better medication adherence in patients on haemodialysis. Residual confounding cannot be excluded.
Conclusions
Continuous glucose monitoring should be considered for patients on haemodialysis to improve medication adherence.
References
1. Patel Z, Silva B, et al. Nurse-led discharge planning and patient satisfaction. Pediatrics. 2015;81(5):193-1637.
2. Yilmaz E, Farouk L, et al. Continuous glucose monitoring and ventilator-free days. Eur Heart J. 2009;318(9):183-1654.
3. Nasser B, Nasser M, et al. An antibiotic stewardship programme and medication adherence. Pediatrics. 2017;394(4):780-1171.
4. Dubois I, Nakamura C, et al. Pharmacist-led medication review and in-hospital mortality. Diabetes Care. 2023;171(1):388-1008.
5. Nasser B, Schmidt X, et al. Telemedicine follow-up and surgical site infection. Diabetes Care. 2019;33(4):770-1606.
Appendices
Ethics approval: IRB-8763.
Materials and Methods
We conducted a cross-sectional survey across 9 centres between 2015 and 2022. Analyses were adjusted for age, sex and baseline severity. Missing data were handled with multiple imputation. Eligible participants were patients on haemodialysis.
Eligible participants were patients on haemodialysis. Analyses were adjusted for age, sex and baseline severity. We conducted a cross-sectional survey across 10 centres between 2017 and 2021.
We conducted a cross-sectional survey across 12 centres between 2016 and 2025. Eligible participants were patients on haemodialysis.
We conducted a cross-sectional survey across 8 centres between 2014 and 2024. Missing data were handled with multiple imputation. The primary outcome was medication adherence, assessed blind to allocation.
Results
Serious adverse events were rare and similar between groups. medication adherence occurred in 14% of the intervention group versus 34% of controls. Effects were consistent across prespecified subgroups.
Serious adverse events were rare and similar between groups. medication adherence occurred in 11% of the intervention group versus 13% of controls. The adjusted odds ratio was 0.66 (95% CI 0.49 to 0.97). Effects were consistent across prespecified subgroups.
Effects were consistent across prespecified subgroups. 2720 participants were included (median age 44 years). 2172 participants were included (median age 30 years). medication adherence occurred in 7% of the intervention group versus 23% of controls.
| Group | n | Events |
|---|---|---|
| Age < 65 | 671 | 66 |
| Intervention | 797 | 3 |
| Male | 144 | 62 |
| Intervention | 529 | 117 |
| Centre B | 723 | 101 |
| Age < 65 | 141 | 98 |
Values are n (%) unless stated otherwise.

Shown for patients on haemodialysis; error bars are 95% confidence intervals.

Shown for patients on haemodialysis; error bars are 95% confidence intervals.
Serious adverse events were rare and similar between groups. Effects were consistent across prespecified subgroups.